"Sou\u010Dasn\u00E9 u\u017E\u00EDv\u00E1n\u00ED furosemidu se srde\u010Dn\u00EDmi glykosidy zvy\u0161uje jejich toxicitu vlivem hypokal\u00E9mie a ji\u017E p\u0159i pod\u00E1v\u00E1n\u00ED b\u011B\u017En\u00FDch d\u00E1vek se mohou objevit zn\u00E1mky jejich p\u0159ed\u00E1vkov\u00E1n\u00ED. Furosemid zvy\u0161uje ototoxicitu aminoglykosidov\u00FDch antibiotik a cisplatiny (\u010Dasto je efekt ireverzibiln\u00ED) a nefrotoxicitu n\u011Bkter\u00FDch cefalosporin\u016F, aminoglykosid\u016F, polymyxin\u016F. Je-li zah\u00E1jena l\u00E9\u010Dba ACE-inhibitory u pacient\u016F, kte\u0159\u00ED byli p\u0159edt\u00EDm intenzivn\u011B l\u00E9\u010Deni furosemidem, m\u016F\u017Ee doj\u00EDt k t\u011B\u017Ek\u00E9 hypotenzi a akutn\u00EDmu selh\u00E1n\u00ED ledvin. P\u0159ed l\u00E9\u010Dbou ACE-inhibitory je nutno vyrovnat vodn\u00ED a elektrolytovou rovnov\u00E1hu. Sou\u010Dasn\u00E9 u\u017E\u00EDv\u00E1n\u00ED furosemidu s kortikoidy nebo laxativy vede ke sn\u00ED\u017Een\u00ED hladiny kalia. V d\u016Fsledku sod\u00EDkov\u00E9 deplece vyvolan\u00E9 furosemidem doch\u00E1z\u00ED k retenci lithia v organismu s rozvojem jeho toxick\u00FDch p\u0159\u00EDznak\u016F. Furosemid m\u016F\u017Ee zvy\u0161ovat \u00FA\u010Dinek kurareformn\u00EDch myorelaxanci\u00ED, salicyl\u00E1t\u016F a teofylinu a sni\u017Euje \u00FA\u010Dinek presorick\u00FDch amin\u016F, antidiabetik a antiuratik.\nP\u0159i spole\u010Dn\u00E9m pod\u00E1v\u00E1n\u00ED furosemidu s jin\u00FDmi hypotenzivy, tricyklick\u00FDmi antidepresivy a fenothiaziny m\u016F\u017Ee doj\u00EDt k v\u00FDrazn\u00E9 hypotenzi.\nNesteroidn\u00ED antirevmatika inhibuj\u00ED p\u016Fsoben\u00ED furosemidu na pr\u016Ftok krve ledvinami v d\u016Fsledku inhibice tvorby prostaglandin\u016F a sni\u017Euj\u00ED tak diuretickou \u00FA\u010Dinnost furosemidu.\n"@cs . . . . . . "4.5. Interakce s\u00A0jin\u00FDmi l\u00E9\u010Div\u00FDmi p\u0159\u00EDpravky a jin\u00E9 formy interakce"@cs . "004.005" .